• Accelero - Your partner in regulatory assay development
    Accelero - Your partner in regulatory assay development

    Accelero - Your partner in regulatory assay development

Berlin Cures GmbH Publishes Promising Phase 1 Data Results

Berlin Cures GmbH is a clinical stage pharmaceutical company developing a short DNA aptamer BC 007 for the treatment of pathogenic autoantibodies against G-protein coupled receptors.

A dose-escalating study evaluated the safety, tolerability, pharmacokinetics and mode of action of BC 007 after a single intravenous infusion. The publication is entitled: "A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects".

BC 007 plasma and urine concentrations were estimated by Accelero Bioanalytic GmbH on the basis of a validated enzyme-linked sandwich hybridisation assay.

The results have been published by Becker NP et al in Clinical Drug Investigation May 2020, 40(5), pages 433-447, doi: 10.1007/s40261-020-00903-9. PubMed ID: 32222912.

Save
Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyze the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline